Transgene

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.
Type
Public
HQ
Illkirch, FR
Size (employees)
146 (est)
Transgene is headquartered in Illkirch, FR

Transgene Office Locations

Transgene has offices in Illkirch, Shanghai, Cambridge, Lyon
Illkirch, FR
Shanghai, CN
Cambridge, US
Lyon, FR

Transgene Metrics

Transgene Summary

Market capitalization

€105 M

Closing share price

€2.73
Transgene's current market capitalization is €105 M.

Transgene Market Value History

Transgene Online Presence

Transgene Company Life

You may also be interested in